Acquired Company

Selecta Biosciences acquired Cartesian Therapeutics, Inc. on November 13, 2023, and the combined company began trading under the RNAC symbol after the merger (RNAC first traded November 14, 2023).

Cartesian Therapeutics Inc. (ticker: RNAC), headquartered in Watertown, Massachusetts, is a pioneering clinical-stage biopharmaceutical company dedicated to developing nanoparticle immunomodulatory therapeutics aimed at enhancing immune responses in diverse therapeutic applications. Leveraging an innovative drug platform, the company is advancing a robust pipeline of biotherapeutics that are currently undergoing clinical evaluation, targeting critical unmet medical needs in the field of immune-mediated therapies. With a strong commitment to scientific innovation and patient-centric solutions, Cartesian Therapeutics is positioned to make a substantial impact in the biopharmaceutical sector, driving advancements that could redefine treatment paradigms. Show more

Location: 7495 NEW HORIZON WAY, FREDERICK, MD, UNITED STATES, 21703, Frederick, MD, 21703, USA | Website: https://www.cartesiantherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

177.6M

52 Wk Range

$5.98 - $20.00

Previous Close

$6.83

Open

$6.88

Volume

71,014

Day Range

$6.76 - $7.04

Enterprise Value

46.82M

Cash

143.4M

Avg Qtr Burn

-15.6M

Insider Ownership

60.90%

Institutional Own.

24.12%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SEL-212 (Pegadricase) Details Chronic refractory gout, Arthritis	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-08 Details Myasthenia gravis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-08 Details Myositis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-08 Details Juvenile dermatomyositis, Juvenile systemic lupus erythematosus (SLE), Juvenile Myasthenia gravis (MG), Anti-neutrophil cytoplasmic antibody associated vasculitis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-15 Details Multiple myeloma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SEL-302 (MMA-101 + ImmTOR) Details Genetic disorder, Methylmalonic acidemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Descartes-08 Details Systemic lupus erythematosus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.